Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-02-20
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-based medicines using CRISPR gene editing, spanning commercial hemoglobinopathy therapy economics and a pipeline of in vivo and cell-based programs.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Scaling gene-editing from first launch to platform
The 2031 outcome hinges on converting early CASGEVY momentum into repeatable center throughput and turning in vivo liver editing into financeable, late-stage assets.

Analysis

Thesis
CASGEVY’s 2025 ramp de-risks real-world demand; if care-delivery capacity and pediatric expansion scale while at least one in vivo liver program becomes clinically credible, CRSP can re-rate into an underwritable multi-asset gene-medicine operator by Feb-2031.
Last Economy Alignment
AI lowers discovery/CMC friction, but CRSP’s value capture is anchored in regulated trust, clinical evidence, and scarce therapy-delivery workflows (not easily commoditized).
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.4x (from 5 most recent analyses)
Reasoning
The stock is ultimately a throughput story plus platform optionality: CASGEVY scales as specialized centers move from “first cases” to repeatable patient flow, while in vivo liver editing progress converts platform science into financeable, partnerable assets. The Last Economy tailwind is faster iteration (target selection, construct design, analytics) and better operational control, but the binding constraints remain regulatory gates and real-world care delivery. If those constraints loosen on schedule, the market can underwrite durable, multi-product economics rather than a single partnered asset plus R&D burn.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risks are (1) CASGEVY scaling being constrained by the care ecosystem rather than demand, (2) partner-paced commercialization translating into slower realized economics, and (3) in vivo programs needing multi-year safety/durability proof that can push the real value inflection beyond 2031.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
They operate behind regulatory gates where trust, evidence, and compliance matter more than cheap cognition, and AI mainly speeds iteration and operations. The threat is that care-delivery capacity and competing modalities cap growth before the platform earns a multi-asset re-rate.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$82.91
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case